Articles tagged with Stem Cell Therapy
A Mayo Clinic study found that stem cells delivered two to three weeks after a heart attack do not improve heart function. The research provides vital information for the field of cell therapy and cautions against seeking stem cell treatment outside the US.
Researchers have combined gene therapy and stem cell transplantation to successfully reverse hemophilia A in large animals, eliminating symptoms and restoring normal activity. However, the treatment's effects may be reduced or shorter due to an immune response developed by the treated animals.
Scientists have cleanly corrected a human gene mutation in a patient's stem cells, using cutting-edge methods to target and correct the sequence of the genome. The corrected gene worked normally, demonstrating the potential for patient-specific therapies.
Professor Peter J. Coffey's pioneering stem cell research aims to replace damaged retinal pigment epithelium cells in Age-Related Macular Degeneration. Clinical trials using his therapy are expected to begin in 2012, offering hope for preventing blindness and restoring sight.
Researchers successfully expanded hematopoietic stem cells a hundredfold by understanding the molecular mechanisms of self-renewal. The study reveals that proliferation, suppression of differentiation and programmed cell death are required for self-renewal.
Researchers at Yale University have successfully converted uterine stem cells into insulin-producing cells, which could lead to the development of a new treatment for Type 1 diabetes. The study found that these stem cells can adopt the characteristics of beta cells in the pancreas and produce insulin in response to glucose.
Researchers at UC Davis Health System used bone marrow-derived adult stem cells to promote bone tissue growth after cervical disc removal. The procedure, part of a nationwide clinical trial, aims to relieve chronic, debilitating pain by eliminating friction between vertebrae and nerve compression.
Researchers at UTHealth report using a patient's own bone marrow stem cells as a safe and feasible treatment for acute stroke. The study, published in Annals of Neurology, showed no severe adverse events among the 10 patients enrolled.
The California Institute for Regenerative Medicine approved five UC Davis Health System teams with research planning grants worth up to $20 million each. These grants aim to develop human clinical trials for treatments of Huntington's disease, critical limb ischemia, airway disease, HIV/AIDS and osteoporosis.
Researchers at Tel Aviv University have discovered that oral mucosa stem cells can be manipulated into fetal-like stem cells with high therapeutic potential for treating neurodegenerative, heart, and autoimmune diseases. The cells can be derived from a small biopsy of tissue and show minimal discomfort and healing time.
Researchers investigated potential effects of G-CSF on chromosomes in healthy PBSC donors and found no replication asynchrony or atypical abnormalities. The study concludes that G-CSF mobilization process is safe for healthy stem cell donors, supporting its use in transplants.
Researchers found that growing blood stem cells for about a week can improve transplantation success rates by reducing immune rejection. The lab-grown HSCs produce an immune system inhibitor on their surface, making them less likely to be rejected and more likely to engraft into the recipient's blood.
UC Davis investigator provides roadmap to overcome obstacles for using induced pluripotent stem cells to treat various human diseases. The technology has the potential to bypass immunological problems inherent in traditional stem cell therapy.
Researchers shared findings on new treatments, predicting treatment outcomes, and patient quality of life issues. A phase II study of carfilzomib showed significant responses in patients with relapsed multiple myeloma.
Scientists at the Salk Institute developed a new technique to generate large numbers of blood cells from patient cells, improving efficiency by 84% compared to previous methods. However, further refinements are needed to produce transplantable HSCs.
A double-blind clinical trial is underway at UTHealth, studying the safety and efficacy of an innovative stem cell therapy for patients up to 19 days after ischemic stroke. The therapy, developed by Aldagen, uses a patient's own bone marrow stem cells to enhance recovery.
A phase II clinical trial found that injections of adult patients' own CD34+ stem cells reduced angina episodes and improved exercise tolerance time. The treatment showed significant improvements in chest pain and exercise duration at six months after treatment.
Researchers at University of Florida have developed a technique to separate neural wheat from chaff in brain cell generation, enabling precise doses of therapeutic neurons. This technology holds promise for treating disorders like Huntington's disease, spinal cord injuries, and Parkinson's disease.
Researchers have successfully reprogrammed adult body cells into iPS cells, which can be taken directly from each patient and genetically redirected to replace ailing cells. While iPS technology holds promise, it still faces challenges and is not yet ready for widespread use.
Researchers developed a serum-free culture for mesenchymal stem cells (MSCs), increasing cellular growth and enhancing specific differentiation capacities. This breakthrough enables the use of 'off-the-shelf' serum-free media, promoting greater control over cell fate regulation and tissue engineering applications.
Notch signaling pathway plays a crucial role in controlling the differentiation of airway basal stem cells, with high levels leading to secretory cells and low levels resulting in ciliated cells. The findings have implications for developing therapies for airway diseases, which are a leading cause of death worldwide.
New research controls stem cell development to direct desired cell types, enabling efficient diagnostics and regenerative medicine therapies. The study's findings could be used to develop manufacturing procedures for producing large quantities of stem cells.
Researchers at Cedars-Sinai Medical Center are developing gene therapy in corneal stem cells to alleviate damage to corneas caused by diabetes. The therapy aims to correct abnormal protein production and restore normal corneal cell turnover, preventing vision loss.
Researchers say stem cell therapeutics may offer therapy through simple cell replacement procedures to restructure damaged organs and tissues. However, factors related to patient selection need careful consideration due to stage and severity of disease, prior therapies, and immunosuppression.
Researchers developed a stem cell treatment enriched with insulin-like growth factor-I (IGF-I) to mend non-healing bone fractures. The study showed that the treated cells became bone cells and helped repair fractures in animal models.
Patients with aggressive non-Hodgkin lymphoma who receive early stem cell transplants have comparable survival rates to those who undergo chemotherapy alone. Researchers urge caution for patients with poor risk factors, recommending careful consultation with their physician.
A new article discusses the current status of neural stem cell research and its translation into clinical therapeutics. The authors highlight the need for a comprehensive and collaborative team effort to overcome hurdles in the process, including funding levels and regulatory approval.
Researchers at Salk Institute successfully edit a diseased gene in patient-specific induced pluripotent stem cells and adult stem cells using a virus-based approach. The method provides an efficient and safe tool for cell engineering, opening the way for gene editing-based stem cell therapies suitable for clinical applications.
Researchers found that human stem cells from bone marrow significantly reduced pulmonary edema and protein in lungs after acute lung injury. hMSC treatment also increased anti-inflammatory proteins, including TSG6 and IL-1RN.
Researchers found that umbilical cord blood-derived mensenchymal stem cells (uMSCs) can delay renal function deterioration and alleviate symptoms of lupus nephritis. Early transplantation with allogenic MSCs showed the most promising results, supporting their potential use in treating systemic lupus erythematosus.
Researchers have discovered that a gene called Sox10 coordinates the balance of cell types in healthy development. This means that it's difficult to get 100% of cells to become one type, even in lab conditions. The study suggests that understanding these balancing mechanisms is crucial for harnessing stem cells in medical applications.
Researchers at the University of Bristol are developing biologically-engineered synthetic liquid polymers to create a permanent solution for cartilage defects. The injectable gel can form three-dimensional scaffolds that encourage healthy cell growth and tissue repair.
Researchers have found that stem cells derived from umbilical cord blood cells and menstrual blood may offer therapeutic benefits for disorders such as stroke, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). These cells can differentiate into various types of cells and have anti-inflammatory properties.
Researchers found that transplanted EPCs from human umbilical cord blood significantly accelerated wound closure in diabetic mouse models. The study showed that growth factors and cytokines produced at the wounded skin sites contributed to healing. This experimental study opens the possibility of using endothelial progenitor cells deri...
Texas Children's Hospital researcher Dr. Jeffrey Jacot receives a National Science Foundation CAREER Award and $450,000 grant to develop tissue engineering therapies using stem cells derived from human amniotic fluid. The goal is to create living heart tissue that can 'patch' or reconstruct hearts with congenital defects.
Researchers from the Walter and Eliza Hall Institute have identified the Erg gene as crucial for blood stem cells' ability to self-renew. This discovery holds promise for developing new therapies using blood stem cells for tissue repair, transplantation, and other applications.
Researchers at UTHealth and Athersys found that MultiStem therapy reduced inflammatory damage in the brain and improved motor skills in rats with ischemic stroke. The study suggests potential benefits of stem cell therapy for treating stroke, with implications for improving recovery outcomes.
A groundbreaking study found that mesenchymal stem cells delivered through the nose improved motor function and increased dopamine levels in rats with Parkinson's disease. This non-invasive approach offers a safer alternative to surgical transplantation.
Researchers aim to replicate Parkinson's disease in lab cells and investigate inflammation to find new therapies. Led by Fred H. Gage, the team will use human induced pluripotent stem cells derived from patients to study neurodegeneration.
Researchers at BWH have engineered human mesenchymal adult stem cells with internal depots that can slowly release agents to influence cell behavior. The cells demonstrated controlled differentiation into bone cells, even affecting distant cells.
Researchers have developed a mathematical model to assess the growth of stem cells and their malignant counterparts. The method, published in PLOS ONE, may aid in developing stem cell therapies for diseases like Alzheimer's and Parkinson's.
A study by George Cotsarelis at the University of Pennsylvania School of Medicine found that balding men retain hair follicle stem cells but lack CD200-rich and CD34-positive progenitor cells. This defect is linked to a transition problem for stem cells, providing potential new therapeutic targets for AGA treatment.
Researchers at UCSF have identified that oligodendroglioma brain tumors arise from progenitor cells rather than neural stem cells. This distinction explains why these tumors are more responsive to therapy, unlike other brain tumors such as glioblastoma multiforme.
Researchers found that human CML stem cells do not rely on BCR-ABL activity for survival, rendering traditional treatments ineffective. This breakthrough highlights the need for new therapeutic strategies to target these resilient cancer cells.
Researchers have discovered that mesenchymal stem cells from umbilical cord blood can suppress inflammation and attenuate collagen-induced arthritis. The study suggests a new potential therapy for rheumatoid arthritis, which currently has limited long-term drug-free remission options.
A recent study published in Stem Cells journal has awarded human cord-blood research with a $10,000 prize for its potential to cure acute kidney injury. The research revealed the regenerative potentials of human cord-blood stem cells as a future cell therapy.
Scientists have identified a novel signal that can control the behavior of stem cells, which holds promise for treating cancer and birth defects. The research, published in Disease Models & Mechanisms, uses bioelectrical therapy to guide stem cells along the correct pathways.
A team of researchers has found a way to increase the number of blood-forming stem cells by using a unique stretchy surface. This breakthrough could revolutionize stem cell transplants by generating up to three times more stem cells than current methods.
Menstrual blood-derived stem cells may aid in brain repair following stroke, with no risk of creating tumors. The study aims to advance the clinical application of self-donor cell therapy for stroke patients.
Researchers have developed a novel strategy for creating patient-specific induced pluripotent stem cells (iPSCs) that exhibits significant advantages over current methods. The new approach uses synthetic modified messenger RNA molecules to reprogram adult cells into iPSCs with high efficiency and safety.
The Northwestern University-led trial assesses the safety and tolerability of human embryonic stem cell-derived oligodendrocyte progenitor cells in paralyzed subjects with spinal cord injuries. The goal is to evaluate if these stem cells improve neuromuscular control or sensation in the trunk or lower extremities.
Researchers at IRCM discover a protein called Gfi1b that regulates blood stem cell activity and mobilization, potentially accelerating the production of new blood cells. This breakthrough could lead to more efficient and safer stem cell therapy for leukemia patients.
The special issue of Translational Research presents an in-depth view of stem cell research, considering its potential for therapy in various human diseases. Despite scientific and technical advancements, serious ethical concerns remain, including issues of privacy and consent.
The NSF-funded program aims to develop engineering methods for stem cell production, focusing on scalable and standardized approaches. The initiative will support 30 new Ph.D. students over five years, with plans for international collaborations.
The American Society of Hematology (ASH) has developed recommendations for advancing regenerative medicine. The key focus areas include recognizing regenerative medicine as a priority at the National Institutes of Health (NIH), re-examining clinical trial methodologies, and improving communication between basic and clinical scientists.
A team led by Drs. Michael A. Matthay and Jae W. Lee found that bone marrow stem cells secreted a protein that restored the lung barrier, preventing fluid and other elements from entering the lungs. The study suggests that this therapy may be a viable option for preventing respiratory failure in critically ill patients.
Researchers at UCSF have successfully purified one type of human embryonic stem cell using a novel, high-throughput strategy that avoids genetic engineering. The technique links two existing technologies and enables the separation of pure stem cells from teratoma-forming cells at a rate of about 25,000 cells per second.
Researchers at Caltech have identified a novel group of microRNAs that regulate the production of hematopoietic stem cells, which produce blood cells. The study found that one particular miRNA enhances the production of mature blood cells but can also induce aggressive leukemia when overexpressed.
A multicentric clinical phase II study led by Professor Dr. Peter Dreger found that allogeneic stem cell transplantation significantly improved tolerance and cured nearly half of patients with therapy-resistant chronic leukemia, regardless of genetic risk profile or prior treatment outcomes.
Researchers at UC San Diego identify new signaling pathway critical for embryonic stem cells' self-propagation, finding that inhibiting this pathway reduces teratoma formation. This breakthrough enables a potential solution to the major obstacle in developing human embryonic stem cell therapies.